Compare Sana Biotechnology Inc (SANA) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and YieldMax TSLA Option Income Strategy ETF is more actively traded (338,271 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| SANA | TSLY | |
|---|---|---|
Market Cap | $836.71M | $697.51M |
Volume | 4,507,444 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $5.92 | $43.35 |
52-Week Low | $2.68 | $20.49 |
Typical Hold Time | 23 Days | 43 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
TSLY trades at $22.45, down 0.66% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent analysis highlights concerns about missing Tesla's upside potential. Support levels cluster around $22 with resistance at $23-24, while RSI indicators remain neutral.
The outlook remains mixed with high yield appeal balanced against structural limitations in capturing Tesla's gains. Key risks include Tesla's volatility regime changes and the ETF's option income strategy constraints. Recent analyst downgrades to Hold reflect diminished upside capture potential amid Tesla's extended capex cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
